Country
Clinical Trials in Venezuela
Studies with at least one site in Venezuela. Open a trial for its sites in Venezuela, who to contact and who can take part.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 5Persistent Spinal Pain Syndrome Type 2 (PSPS-T) Lower Spine, Chronic Low Back Pain
SPINE-RISK VE: Multimodal Predictive Model for Failed Back Surgery Syndrome in Venezuelan Surgical Patients
SPINE-RISK VE is a prospective multicenter cohort study designed to develop and internally validate a multimodal preoperative predictive model for Failed Back Surgery Syndrome (FBSS), now classified as Persistent Spinal Pain…
- Conditions
- Persistent Spinal Pain Syndrome Type 2 (PSPS-T) Lower Spine, Chronic Low Back Pain, Postoperative Pain, Lumbar Spine Surgery
- Trial name
- SPINE-RISK VE (NCT07693517)
- Testing
- SPINE-RISK VE multimodal preoperative assessment
- Where
- Venezuela
- Volunteers
- 150 people
- Sponsor
- juan jose valero quintero,MD
Masked Hypertension
MASked-unconTrolled hypERtension Management Based on Office BP or on Out-of-office (Ambulatory) BP Measurement
MASTER study is a 4-year prospective, randomized, open-label, blinded-endpoint study (PROBE) comparing 2 management strategies 1) office BP as a guide to treatment, or 2) 24-hour ABP as a guide to treatment.
- Trial name
- MASTER (NCT02804074)
- Testing
- Optimization of antihypertensive treatment based on office BP, Optimization of antihypertensive treatment based on 24-hour ABPM
- Where
- 2 sites in Italy, Venezuela
- Volunteers
- 1,240 people
- Sponsor
- Istituto Auxologico Italiano
Limb Fracture, Bone Loss
An International, Multicenter, Prospective Registry on Post-traumatic Long Bones Defects
Long bone defect (LBD) is defined as a focalized loss of bone tissue in any long bone of the upper or lower extremity. Long bone defects are a complex problem, that may arise as a complication of many different pathologies, such…
- Trial name
- NCT04112992
- Testing
- Any treatment that is used for a defect of any long bone
- Where
- 21 sites in United States, Australia and 12 more
- Volunteers
- 600 people
- Sponsor
- AO Innovation Translation Center
Metastatic Breast Cancer
A Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of ConvitVax in Metastatic Breast Cancer
This is a proof-of-concept, single-center, non-randomized, open-label, phase 1b/2 study to evaluate the safety and efficacy of ConvitVax, a simple, low cost (of manufacture), personalized, potentially safe and effective breast…
- Trial name
- NCT06023277
- Testing
- ConvitVax
- Where
- 3 sites in United States, Venezuela
- Volunteers
- 40 people
- Sponsor
- Jacinto Convit World Organization Inc.
Bariatric Surgery Candidate, GERD
9-Step Magnetic Bariatric Revisional Surgery
RYGB represents one of the best alternatives for weight loss in obese patients achieving a weight loss of up to 60% and a resolution of comorbidities of 70%.
- Conditions
- Bariatric Surgery Candidate, GERD, Revisional Bariatric Surgery
- Trial name
- NCT04945304
- Testing
- magnetic bariatric surgery, Magnetic gastric bypass
- Where
- Venezuela
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Unidad Internacional de Cirugia Bariatrica y Metabolica
Completed, with results posted
All 54Non Small Cell Lung Cancer, Lung Cancer
Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients
Non-small cell lung cancer (NSCLC) can be treated with drugs that kill tumour cells, stop them from dividing, or stop the growth of the blood supply that cancers need to grow and spread.
- Trial name
- ZEAL (NCT00418886)
- Testing
- Vandetanib, Pemetrexed
- Where
- 110 sites in United States, Argentina and 19 more
- Volunteers
- 698 people
- Sponsor
- Genzyme, a Sanofi Company
Breast Cancer
A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
This two-cohort, open-label, multicenter study will assess the safety, efficacy and tolerability of trastuzumab emtansine in participants with HER2-positive locally advanced breast cancer (LABC) or metastatic breast cancer (mBC)…
- Trial name
- NCT01702571
- Testing
- Trastuzumab Emtansine
- Where
- 300 sites in Argentina, Australia and 41 more
- Volunteers
- 2,185 people
- Sponsor
- Hoffmann-La Roche
Breast Neoplasms
A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
This multicenter, two-cohort, non-randomized, open-label study will evaluate the safety and tolerability of assisted and self-administered SC Herceptin as adjuvant therapy in participants with early HER2-positive breast cancer…
- Trial name
- SafeHER (NCT01566721)
- Testing
- Herceptin
- Where
- 437 sites in Albania, Algeria and 57 more
- Volunteers
- 2,577 people
- Sponsor
- Hoffmann-La Roche
Stroke, Atrial Fibrillation
GLORIA-AF Registry Program - Second and Third Phases
In this part of the Registry Program patients with non-valvular atrial fibrillation (AF) at risk for stroke are enrolled to characterize the target population and to collect real world data on important outcome events.
- Trial name
- NCT01468701
- Where
- 666 sites in United States, Argentina and 19 more
- Volunteers
- 37,235 people
- Sponsor
- Boehringer Ingelheim
Bipolar Mania, Bipolar Disorder
Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed)
The purpose of this study is to determine if ziprasidone plus a mood stabilizer will continue to be a safe and effective treatment regimen for adults with Bipolar I Disorder (manic or mixed symptoms) after they have achieved 8…
- Trial name
- NCT00280566
- Testing
- Ziprasidone Oral Capsule
- Where
- 107 sites in United States, Chile and 11 more
- Volunteers
- 584 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.